Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type IV collagen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Type IV collagen. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005999-13 Sponsor Protocol Number: D8180C00034 Start Date*: 2008-02-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease ...
    Medical condition: Prostate Cancer or Breast Cancer with Metastatic Bone Disease Cáncer de próstata o de mama con metástasis óseas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) SE (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003699-60 Sponsor Protocol Number: KIBB01 Start Date*: 2018-09-28
    Sponsor Name:Karolinska Institutet
    Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal...
    Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.
    Disease:
    Population Age: In utero, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000087-16 Sponsor Protocol Number: CA182-026 Start Date*: 2009-03-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Lette...
    Medical condition: Subjects with Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000605-72 Sponsor Protocol Number: CB+MSCforEB Start Date*: 2014-02-06
    Sponsor Name:Universitair Medisch Centrum Utrecht
    Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa
    Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004513-15 Sponsor Protocol Number: Start Date*: 2005-11-28
    Sponsor Name:Univ. Prof. Dr. Christoph Zielinski
    Full Title: ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE
    Medical condition: Metastatic bone disease due to breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002158-35 Sponsor Protocol Number: IVA_01_ODI_HMPS_17_002 Start Date*: 2017-11-16
    Sponsor Name:Inventiva S.A.
    Full Title: A phase IIa study to investigate safety, Pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI.
    Medical condition: Mucopolysaccharidosis (MPS) type VI.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028095 Mucopolysaccharidosis IV PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004835-26 Sponsor Protocol Number: D169AL00005 Start Date*: 2021-05-24
    Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST
    Full Title: Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubuloi...
    Medical condition: Chronic Kidney Deseas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10050441 Chronic renal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016748-38 Sponsor Protocol Number: MAL-REG_01 Start Date*: Information not available in EudraCT
    Sponsor Name:Free State of Bavaria rep. by the Univ. of Regensburg, rep. by the Regensburg Univ. Hospital
    Full Title: Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and...
    Medical condition: actinic keratoses and photoaged skin
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000614 Actinic keratosis LLT
    12.0 10065944 Photodamaged skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010813-57 Sponsor Protocol Number: RA0010 Start Date*: 2009-08-28
    Sponsor Name:UCB Celltech
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, single dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of intravenous and subcutaneous CDP6038 in...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002887-29 Sponsor Protocol Number: Uni-Koeln-1574 Start Date*: 2013-02-13
    Sponsor Name:University of Cologne
    Full Title: Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab
    Medical condition: In this study we will evaluate the efficacy of Denosumab in children with Osteogenesis imperfecta. Subjects will be treated every 12 weeks over 36 weeks with Denosumab 1mg/kg body weight s.c.. Effi...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000212-41 Sponsor Protocol Number: 206246 Start Date*: 2017-08-10
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants with Pulmonary Arterial Hypertension.
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077729 Pulmonary arterial hypertension WHO functional class III LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077740 Pulmonary arterial hypertension WHO functional class II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005096-27 Sponsor Protocol Number: MBPS205 Start Date*: 2017-06-23
    Sponsor Name:Mereo BioPharma 3 Ltd.
    Full Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusu...
    Medical condition: Osteogenesis imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003818-24 Sponsor Protocol Number: DC2015RED01 Start Date*: 2015-12-11
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked trans...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006065-16 Sponsor Protocol Number: FP-006-IM Start Date*: 2007-03-19
    Sponsor Name:Nycomed Danmark ApS
    Full Title: A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteopor...
    Medical condition: Primary postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003230-26 Sponsor Protocol Number: MIV-711-201 Start Date*: 2016-03-23
    Sponsor Name:Medivir AB
    Full Title: A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis
    Medical condition: Knee Joint Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-002695-37 Sponsor Protocol Number: CLIN-60190-453 Start Date*: 2023-04-27
    Sponsor Name:Ipsen Bioscience, Inc.
    Full Title: A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary ...
    Medical condition: Adults patients with Primary Sclerosing Cholangitis (PSC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000745-21 Sponsor Protocol Number: P1200_12 Start Date*: 2012-12-10
    Sponsor Name:Schriners Hospitals for Children
    Full Title: An international, multicenter, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta
    Medical condition: Children suffering from severe Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003511-37 Sponsor Protocol Number: K-877-301 Start Date*: 2017-01-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double­Blind, 12-Week Study With a 40-Week, Active-Controlled, Double­Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult ...
    Medical condition: severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011251-48 Sponsor Protocol Number: CNTO888PCR2001 Start Date*: 2009-08-28
    Sponsor Name:Janssen Biologics B.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:26:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA